Vertex Pharmaceuticals Incorporated
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $3.95B | $-535.6M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B | $2.10B |
| Depreciation & Amortization | $209.8M | $207.2M | $181.3M | $148.3M | $125.6M | $109.5M | $106.9M | $72.4M |
| Depreciation | $155.8M | $160.4M | $167.8M | $148.3M | $125.6M | $109.5M | $106.9M | $72.4M |
| Amortization | $20.2M | $20.2M | $1.7M | — | — | — | — | — |
| Stock-Based Compensation | $685.9M | $698.5M | $581.2M | $491.3M | $441.4M | $429.5M | $360.5M | $325.0M |
| Net Cash from Operating Activities | $3.63B | $-492.6M | $3.54B | $4.13B | $2.64B | $3.25B | $1.57B | $1.27B |
| Investing Activities | ||||||||
| Capital Expenditures | $437.6M | $297.7M | $200.4M | $204.7M | $235.0M | $259.8M | $75.4M | $95.4M |
| Business Acquisitions | — | $0 | $0 | $295.9M | $0 | $0 | $1.15B | $0 |
| Net Cash from Investing Activities | $-945.4M | $-3.77B | $-3.14B | $-321.1M | $-340.9M | $99.4M | $-1.24B | $-202.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $2.02B | $1.18B | $427.6M | $0 | $1.43B | $539.1M | $186.0M | $350.0M |
| Net Cash from Financing Activities | $-2.26B | $-1.49B | $-562.2M | $-67.7M | $-1.48B | $-505.3M | $126.8M | $-71.2M |
| Net Change in Cash | $515.6M | $-5.80B | $-139.7M | $3.71B | $811.2M | $2.87B | $462.4M | $990.7M |
| Free Cash Flow | $3.19B | $-790.3M | $3.34B | $3.93B | $2.41B | $2.99B | $1.49B | $1.17B |